Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
August 25th
Marc ZERBOLA CHALLANDE
If for a long time, nuclear energy had this ominous image of “polluting energy,” and because of its waste, minds have quickly evolved, and maybe countries have started to build nuclear plants as it can provide energetical independency. In the long term, this energy will be used more, which is why you might consider investing in uranium stocks.
Nuclear energy protects air quality. Compared to other sources, it is zero-emission clean energy. The United States avoided more than 471 million metric tons of carbon dioxide emissions in 2020. It is the equivalent of removing 100 million cars from the road and represents more than all other clean energy sources combined. Infrastructure-wise, nuclear is also a great winner. It has a light footprint, and for a 1,000-megawatt atomic facility in the USA that would need a little more than 1 square mile to operate, windfarms require 360 times more land area, according to the Nuclear Energy Institute.
Regarding nuclear waste, the WNA claims, “In all countries using nuclear energy, there are well-established procedures for storing, managing and transporting such wastes, funded from electricity users. Wastes are contained and managed, not released. Storage is safe and secure; plans are well in hand for eventual disposal.”
According to the International Atomic Energy Agency (IAEA), the high case projection has global nuclear-generating capacity increasing from 392 GWe in 2019 to 475 GWe by 2030, 622 by 2040, and 715 by 2050. Choosing nuclear options can result in several cases, whether it be for environmental or electric freedom. Recently, European countries have suffered from energetic dependency as many countries bought Russia’s resources. According to the Nuclear Power Association, about 440 reactors operate in 32 countries. About 55 plants are currently being constructed in 19 countries, notably China, India, Russia, and the United Arab Emirates. About 100 power reactors with a total gross capacity of approximately 100,000 MWe are on order or planned, and over 300 more are proposed. Currently, most reactors are in Asia, with fast-growing economies and rapidly-rising electricity demand. About 30 countries are considering, planning, or starting nuclear power programs.
Pegasus Resources stock (PEGA.V) is an exciting play as nuclear power has a unique spot in transitioning from fossil fuels to sustainable energy.Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company focusing on North America’s uranium, gold, and base metal properties.
Pegasus currently holds four Uranium properties located northeast of the prolific Athabasca Basin of northern Saskatchewan:
The company owns plenty of other projects, including:
The Athabasca Basin is a region in the Canadian Shield of northern Saskatchewan and Alberta, Canada. It is best known as the world’s leading source of high-grade uranium and currently supplies about 20% of the world’s uranium. The Athabasca Basin covers an area of almost 100,000 square kilometers and hosts the world’s largest producing uranium mine, Cigar Lake.
August 24th: Pegasus has announced that based on the recent radon survey results, in combination with the historical geophysical work, Pegasus is looking to advance its Pine Channel Uranium Project, located in the Athabasca Basin region of northern Saskatchewan, to the drilling stage.
The radon survey comprised two grids, Grid A and Grid B, consisting of 461 and 217 radon sampling points. Grid A spans roughly 3km east to west, starting along the shoreline and extending approximately 850m to the south. Grid B is 1300m by 750m and is located south of Grid A.
“Exciting times for Pegasus investors. The radon survey came back, and we have drill-ready targets!” stated Chris Timmins, President of Pegasus Resources. “Pegasus, over the coming weeks, will apply for the necessary permits and consult with the group representing the northern communities and First Nations groups, the Ya’ thi Néné Lands and Resources (YNLR) office, leading up to a winter drill program.”
If the company’s share price hasn’t lost any value Year-over-Year, its market cap is meager to the company’s potential opportunities. With a current $0.04 share price, it is at its 52-week low, far from its $0.11 reached on April 2022. With an RSI data worth 46, the stock is neither overbought nor oversold territory (30 and under, 70 and above).
According to TradingView technical, the stock is currently a BUY (13 BUY, 9 NEUTRAL, 4 SELL).
Pegasus Resources (PEGA.V) is located in the Athabasca Basin, which gathers 20% of the worldwide uranium resources;
The company is significantly undervalued regarding all the news provided;
Many technical indicators show the share price is a BUY;
Nuclear is the cleanest energy in the world.
Marc has been involved in the Stock Market Media Industry for the last +5 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Capital where he was head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including breaking news technology, metals & mining markets.
©2024 10xAlerts